LBT Innovations Limited (AU:LBT) has released an update.
LBT Innovations Limited has announced a lucrative contract with NovaCina for the sale of its APAS® Independence instrument and accompanying PharmaQC software, with delivery expected in June 2024. This deal, worth over $0.7 million, includes a five-year license for software, maintenance, and support, underscoring LBT’s expanding footprint in the biopharmaceutical market. The technology promises to enhance quality and efficiency in NovaCina’s aseptic manufacturing processes through AI-driven automation.
For further insights into AU:LBT stock, check out TipRanks’ Stock Analysis page.
Click Here to Read the Full Original Article at TipRanks Financial Blog…
